Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas

19 Mar 2017

Abstract excerpt

Mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 are among the first genetic alterations observed during the development of lower-grade glioma (LGG). LGG-associated IDH mutations confer gain-of-function activity by converting α-ketoglutarate to the oncometabolite R-2-hydroxyglutarate (2HG). Clinical samples and gene expression data from The Cancer Genome Atlas (TCGA) demonstrate reduced expression of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glioma Diagnosis and Treatment
Share to Immune cells in cancer
Share to Neuroinflammation and Neurodegeneration Mechanisms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28319047
DOI: 10.1172/jci90644

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomasPMID 28319047Read ↗

Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma.Semantic proximity Read ↗

IDH1 Mutant Glioma Favors Group 3 Innate Lymphoid Cells and Is Resistant to Immune Checkpoint Expression.Semantic proximity Read ↗

Resisting fatal attraction: a glioma oncometabolite prevents CD8+ T cell recruitment.Semantic proximity Read ↗

Implications of IDH mutations on immunotherapeutic strategies for malignant glioma.Semantic proximity Read ↗

Immunotherapy Approaches in Isocitrate-Dehydrogenase-Mutant Low-Grade GliomaSemantic proximity Read ↗

Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in miceSemantic proximity Read ↗

ISG20 promotes local tumor immunity and contributes to poor survival in human gliomaSemantic proximity Read ↗

Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas.Semantic proximity Read ↗

Potential of IDH mutations as immunotherapeutic targets in gliomas: a review and meta-analysis.Semantic proximity Read ↗

Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors.Semantic proximity Read ↗

Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting IDH-MutationsSemantic proximity Read ↗

Inhibition of 2-Hydroxyglutrate Elicits Metabolic-reprograming and Mutant IDH1 Glioma ImmunitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.